NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/21/13 -- BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company's current and upcoming clinical trial and scientific conference activities.
Clinical Trial Activities
Brainstorm recently performed the 5th transplantation in its ongoing Phase IIa clinical trial with NurOwn at the Hadassah Medical Center in Jerusalem. In this Phase IIa trial, 12 ALS patients are receiving combined intramuscular and intrathecal administration of NurOwn cells, in three cohorts, with increasing doses. The study participants will be monitored for six months following transplantation. In a recent radio interview on Israel's "Galei Tzahal," Professor Dimitrios Karussis, Principal Investigator, discussed the current trial as well as the results of the recently completed Phase I/II trial, which he referred to as "very encouraging." A recording of the interview and English translation can be accessed on BrainStorm's website at: http://bit.ly/114HYiQ.
In addition, preparation of the Company's IND submission for the upcoming Phase II trial in the US remains on schedule. BrainStorm anticipates patient enrollment to begin later this year.
Upcoming Scientific Conferences
Professor Dimitrios Karussis, Principal Investigator of BrainStorm's clinical trials at Jerusalem's Hadassah Medical Center, will make an oral presentation at Twenty-third Meeting of the European Neurological Society (ENS) to be held June 8-11 in Barcelona, Spain. The presentation is scheduled for the Motor Neuron Disease session on Sunday, June 9th at 16:00.
Dr. Adrian Harel, BrainStorm's Director of R&D, will be presenting at the IATI Biomed Israel 2013 Conference to be held June 10-12 in Tel Aviv. The presentation will be given on Tuesday, June 11th at 14:50.
Professor Daniel Offen, BrainStorm's Chief Scientific Advisor, will deliver a poster presentation at the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), to be held June 12-15 in Boston, MA. Prof. Offen will present in Poster Session I on Wednesday, June 12th at 6:30 pm.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
BrainStorm Cell Therapeutics Inc.
Mr. Alon Natanson
LifeSci Advisors, LLC
Most Popular Stories
- Koch Brothers Step up Anti-Obamacare Campaign
- FDIC Sues Big Banks Over Rate Manipulation
- Vybz Kartel Convicted of Murder
- FDIC Accuses Big Banks of Fraud, Conspiracy
- Stocks Close Lower Ahead of Crimea Vote
- U.S. Consumer Sentiment Falls in Early March
- Ulta Shares Look Good on Strong Q4
- Is Malaysian Airlines Flight 370 in Andaman Sea?
- Jittery Investors Dumping Russian Stocks
- SoCalGas Reaches Record Spend on Diversity Suppliers